Press Releases

July 13, 2022
Gossamer Bio Announces $120 Million Private Placement Financing
SAN DIEGO --(BUSINESS WIRE)--Jul. 13, 2022-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced today it has agreed to
Additional Formats
June 9, 2022
Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH
SAN DIEGO --(BUSINESS WIRE)--Jun. 9, 2022-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the publication of
Additional Formats